Mineralys Director Sells $75k in MLYS Stock Director Daphne Karydas sold $75,000 of MLYS stock on Apr 2, 2026 (Investing.com); disclosure timely under SEC Form 4 rules and likely low market impact.

Mineralys Director Sells $75k in MLYS Stock: Director Daphne Karydas sold $75,000 of MLYS stock on Apr 2, 2026 (Investing.com); disclosure timely under SEC Form 4 rules and likely low market impact. 👈 Read full analysis #Investing #Finance #StockMarket #MLYS #Mineralys

Mineralys Therapeutics Completes Enrollment – Ysios Capital Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025

#PortfolioNews I Our #quoted #portfolio company #Mineralys #MLYS completed Enrollment in Explore-CKD Phase 2 Trial of #Lorundrostat for the Treatment of #Hypertension in Subjects with Stage 2 to 3b chronic kidney disease #CKD and #Albuminuria

👉 https://buff.ly/4gqM4t2

#vc #ClinicalTrials